Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Public Equities L.P. Invus bought 180,727 shares of the business’s stock in a transaction dated Friday, November 17th. The shares were bought at an average price of $10.11 per share, with a total value of $1,827,149.97. The transaction was disclosed in a filing with the SEC, which is available at this link.
Public Equities L.P. Invus also recently made the following trade(s):
- On Friday, November 10th, Public Equities L.P. Invus acquired 145,680 shares of Lexicon Pharmaceuticals stock. The stock was acquired at an average price of $9.74 per share, with a total value of $1,418,923.20.
- On Tuesday, November 14th, Public Equities L.P. Invus acquired 575,946 shares of Lexicon Pharmaceuticals stock. The stock was acquired at an average price of $9.64 per share, with a total value of $5,552,119.44.
Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ LXRX) traded down $0.08 during trading on Tuesday, hitting $10.17. 540,252 shares of the company traded hands, compared to its average volume of 810,454. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.65 and a current ratio of 1.66. Lexicon Pharmaceuticals, Inc. has a 12 month low of $8.07 and a 12 month high of $18.00.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.07. Lexicon Pharmaceuticals had a negative net margin of 165.69% and a negative return on equity of 111.68%. The firm had revenue of $26.94 million for the quarter, compared to analyst estimates of $27.97 million. During the same period in the previous year, the firm posted ($0.35) EPS. The company’s revenue for the quarter was down 2.8% compared to the same quarter last year. equities research analysts forecast that Lexicon Pharmaceuticals, Inc. will post -1.43 EPS for the current year.
Several analysts have weighed in on the stock. Wedbush reiterated an “outperform” rating and issued a $38.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Thursday, November 30th. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, November 14th. Needham & Company LLC reissued a “buy” rating and issued a $21.00 target price on shares of Lexicon Pharmaceuticals in a report on Sunday, September 17th. Finally, BidaskClub lowered shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. Lexicon Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $28.50.
Several hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC lifted its position in shares of Lexicon Pharmaceuticals by 0.9% in the 2nd quarter. FMR LLC now owns 15,785,280 shares of the biopharmaceutical company’s stock worth $259,668,000 after purchasing an additional 137,421 shares during the period. Vanguard Group Inc. lifted its position in shares of Lexicon Pharmaceuticals by 16.3% in the 1st quarter. Vanguard Group Inc. now owns 4,168,301 shares of the biopharmaceutical company’s stock worth $59,773,000 after purchasing an additional 585,222 shares during the period. USS Investment Management Ltd acquired a new position in shares of Lexicon Pharmaceuticals in the 2nd quarter worth approximately $57,705,000. Eagle Asset Management Inc. lifted its position in shares of Lexicon Pharmaceuticals by 0.3% in the 2nd quarter. Eagle Asset Management Inc. now owns 2,861,065 shares of the biopharmaceutical company’s stock worth $47,064,000 after purchasing an additional 8,756 shares during the period. Finally, State Street Corp lifted its position in shares of Lexicon Pharmaceuticals by 19.9% in the 2nd quarter. State Street Corp now owns 1,967,255 shares of the biopharmaceutical company’s stock worth $32,363,000 after purchasing an additional 326,088 shares during the period.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/05/insider-buying-lexicon-pharmaceuticals-inc-lxrx-director-purchases-1827149-97-in-stock.html.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.